Daniel Barber
Net Worth
Last updated:
What is Daniel Barber net worth?
The estimated net worth of Mr. Daniel Barber is at least $5,348,923 as of 8 Jun 2022. He owns shares worth $355,963 as insider and has received compensation worth at least $4,992,960 in Aquestive Therapeutics, Inc..
What is the salary of Daniel Barber?
Mr. Daniel Barber salary is $713,280 per year as Senior Vice President & Chief Operating Officer in Aquestive Therapeutics, Inc..
How old is Daniel Barber?
Mr. Daniel Barber is 49 years old, born in 1976.
What stocks does Daniel Barber currently own?
As insider, Mr. Daniel Barber owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | Senior Vice President & Chief Operating Officer | 91,743 | $3.88 | $355,963 |
What does Aquestive Therapeutics, Inc. do?
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Daniel Barber insider trading
Aquestive Therapeutics key executives
Aquestive Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Mr. Daniel Barber (49) Senior Vice President & Chief Operating Officer
- Mr. Keith J. Kendall (67) Chief Executive Officer, Pres & Director